Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“I’m heading to New York for the United Nations General Assembly (UNGA) United Nations High-Level Week to join the International Alliance for Personalised Medicine (IAPM) for critical discussions on translating precision medicine innovation into patient benefit.
Speaking at United Nations IAPM sessions on September 23–24 with leaders across healthcare, policy, science, and industry on the real work of personalised medicine: closing the gap between discovery and access.”
Other posts featuring Vivek Subbiah on OncoDaily.